In the synthesis of l-phenyl-5-substituted amino-4-pyrazole N-alkyl amide, it was found for the first time that one of the two aromatic amido groups in the molecule of 1-phenyl-5-benzoyl amino-4-pyrazole N-alkyl amide...In the synthesis of l-phenyl-5-substituted amino-4-pyrazole N-alkyl amide, it was found for the first time that one of the two aromatic amido groups in the molecule of 1-phenyl-5-benzoyl amino-4-pyrazole N-alkyl amide was reduced selectively by LiAlH_4. new conclusion was drawn after several experiments have been done that ortho-amino(or substituted amino)aryl amide or the aryl amide with its ortho substituent which can be reduced into an amino group(or substituted amino group)can not be reduced by LiAlH_4. It was further rationalized by quantum chemical calculation.展开更多
An equation to express ion exchange selectivity coefficient was derived and used for cal- culating that of PPY film with the results obtained by cyclic voltamrnetric measurement.PPY film was synthesized by electrochem...An equation to express ion exchange selectivity coefficient was derived and used for cal- culating that of PPY film with the results obtained by cyclic voltamrnetric measurement.PPY film was synthesized by electrochemical method in aqueous solution using K_4Fc(CN)_6 as supporting electrolyte, and the anions were doped into the film.Ion exchange behaviour of doped Fe(CN)_6^(3-/4-)in the PPY film with Cl^-,NO_3^- or F^- ions in solution has been studied,and the corresponding ion exchange selec- tivity coefficients were determined.展开更多
BACKGROUND： Epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI） targeted treatment has been a standard therapy for advanced non-small cell lung cancer （NSCLC）, but it is not tolerated well by al...BACKGROUND： Epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI） targeted treatment has been a standard therapy for advanced non-small cell lung cancer （NSCLC）, but it is not tolerated well by all patients. In China, some studies have reported that traditional Chinese medicinal herbs （TCMHs） may increase efficacy and reduce toxicity when combined with EGFR-TKI, but outside of China few studies of this kind have been attempted. OBJECTIVE： This study is intended to systematically review the existing clinical evidence on TCMHs combined with EGFR-TKI for treatment of advanced NSCLC. SEARCH STRATEGY： PubMed, the Cochrane Library, the Excerpta Medica Database （EMBASE）, the China BioMedical Literature （CBM）, and the China National Knowledge Infrastructure （CNKI） and web site of the American Society of Clinical Oncology （ASCO）, the European Society for Medical Oncology （ESMO）, the World Conference of Lung Cancer （WCLC） were searched; the search included all documents published in English or Chinese before October 2013. INCLUSION CRITERIA： We selected randomized controlled trials based on specific criteria, the most important of which was that a TCMH plus EGFR-TKI treatment group was compared with an EGFR-TKI control group in patients with advanced NSCLC. DATA EXTRACTION AND ANALYSIS： The modified Jadad scale was used to assess the quality of studies. For each included study, patient characteristics, treatment details, therapeutic approach and clinical outcomes were collected on a standardized form. When disagreements on study inclusion or data extracted from a study emerged, the consensus of all coauthors provided the resolution. The clinical outcome metrics consisted of objective response rate （ORR; complete response ＋ partial response divided by the total number of patients）, disease control rate （DCR; complete response ＋ partial response ＋ no change divided by the total number of patients）, survival rate, improved or stabilized Karnofsky performance status （KPS）, and severe toxicity. RevMan 5.0 software was used for data syntheses and analyses. Risk ratio （RR） and 95% confidence interval （CI） were calculated; if the hypothesis of homogeneity was not rejected （P〉0.1, I2〈50%）, the fixed-effect model was used to calculate the summary RR and the 95% CI. Otherwise, a random-effect model was used.展开更多
基金Project supported by National Natural Science Foundation of China.
文摘In the synthesis of l-phenyl-5-substituted amino-4-pyrazole N-alkyl amide, it was found for the first time that one of the two aromatic amido groups in the molecule of 1-phenyl-5-benzoyl amino-4-pyrazole N-alkyl amide was reduced selectively by LiAlH_4. new conclusion was drawn after several experiments have been done that ortho-amino(or substituted amino)aryl amide or the aryl amide with its ortho substituent which can be reduced into an amino group(or substituted amino group)can not be reduced by LiAlH_4. It was further rationalized by quantum chemical calculation.
基金This work was financially supported by the National Natural Science Foundation of China.
文摘An equation to express ion exchange selectivity coefficient was derived and used for cal- culating that of PPY film with the results obtained by cyclic voltamrnetric measurement.PPY film was synthesized by electrochemical method in aqueous solution using K_4Fc(CN)_6 as supporting electrolyte, and the anions were doped into the film.Ion exchange behaviour of doped Fe(CN)_6^(3-/4-)in the PPY film with Cl^-,NO_3^- or F^- ions in solution has been studied,and the corresponding ion exchange selec- tivity coefficients were determined.
基金supported by business proposals research and special topics of 2012 Annual National TCM Clinical Research Base (No. JDZX2012119)
文摘BACKGROUND： Epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI） targeted treatment has been a standard therapy for advanced non-small cell lung cancer （NSCLC）, but it is not tolerated well by all patients. In China, some studies have reported that traditional Chinese medicinal herbs （TCMHs） may increase efficacy and reduce toxicity when combined with EGFR-TKI, but outside of China few studies of this kind have been attempted. OBJECTIVE： This study is intended to systematically review the existing clinical evidence on TCMHs combined with EGFR-TKI for treatment of advanced NSCLC. SEARCH STRATEGY： PubMed, the Cochrane Library, the Excerpta Medica Database （EMBASE）, the China BioMedical Literature （CBM）, and the China National Knowledge Infrastructure （CNKI） and web site of the American Society of Clinical Oncology （ASCO）, the European Society for Medical Oncology （ESMO）, the World Conference of Lung Cancer （WCLC） were searched; the search included all documents published in English or Chinese before October 2013. INCLUSION CRITERIA： We selected randomized controlled trials based on specific criteria, the most important of which was that a TCMH plus EGFR-TKI treatment group was compared with an EGFR-TKI control group in patients with advanced NSCLC. DATA EXTRACTION AND ANALYSIS： The modified Jadad scale was used to assess the quality of studies. For each included study, patient characteristics, treatment details, therapeutic approach and clinical outcomes were collected on a standardized form. When disagreements on study inclusion or data extracted from a study emerged, the consensus of all coauthors provided the resolution. The clinical outcome metrics consisted of objective response rate （ORR; complete response ＋ partial response divided by the total number of patients）, disease control rate （DCR; complete response ＋ partial response ＋ no change divided by the total number of patients）, survival rate, improved or stabilized Karnofsky performance status （KPS）, and severe toxicity. RevMan 5.0 software was used for data syntheses and analyses. Risk ratio （RR） and 95% confidence interval （CI） were calculated; if the hypothesis of homogeneity was not rejected （P〉0.1, I2〈50%）, the fixed-effect model was used to calculate the summary RR and the 95% CI. Otherwise, a random-effect model was used.
